Literature DB >> 56991

Production of antisera with specificity for malignant melanoma and human fetal skin.

D Fritze, D H Kern, C R Drogemuller, Y H Pilch.   

Abstract

Complement-dependent cytotoxic antibodies to common cell surface antigens of cultured melanoma cells were produced in guinea pigs. At appropriate dilution, melanoma antisera were cytotoxic only to melanoma target cells. Following absorption with pooled lymphoid cells, additional absorption with melanoma cells but not absorption with fibroblasts or carcinoma cells was found to remove all cytotoxic activity from melanoma antisera. Absorption with human fetal skin cells but not with autologous fetal visceral cells was found to remove cytotoxicity from melanoma antisera. Tissue type-specific antigens may be shared by human malignant melanomas and fetal skin of black racial origin (at 16 to 18 weeks of gestation). The methods may be useful in the production of xenogeneic antisera with "operational monospecificity" for common melanoma-specific antigens. Sera from 47 patients with malignant melanoma failed to evidence specific cytotoxicity for melanoma target cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56991

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen.

Authors:  K K Hunt; M Shibata; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Rapid adsorption of a foetal calf serum component by mammalian cells in culture. A potential source of artifacts in studies of antisera to cell-specific antigens.

Authors:  R S Kerbel; D Blakeslee
Journal:  Immunology       Date:  1976-12       Impact factor: 7.397

Review 3.  Transfer of tumor specific immunity with "immune" RNA: prospects for the treatment of human cancer.

Authors:  D Fritze; D H Kern; Y H Pilch
Journal:  Klin Wochenschr       Date:  1976-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.